Published in Nat Immunol on October 26, 2015
p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells. Cancer Cell (2016) 0.93
Inflammatory networks underlying colorectal cancer. Nat Immunol (2016) 0.88
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. Front Immunol (2016) 0.83
p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer. FEBS Lett (2016) 0.82
Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene (2016) 0.79
Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. Carcinogenesis (2016) 0.76
Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together. Front Immunol (2016) 0.76
Lymphotoxin in physiology of lymphoid tissues - Implication for antiviral defense. Cytokine (2016) 0.76
AllergoOncology - The impact of Allergy in Oncology. EAACI Position Paper. Allergy (2016) 0.76
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function. Front Immunol (2017) 0.75
Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4(+) tumor-infiltrating lymphocytes. Oncoimmunology (2016) 0.75
Hepatocellular carcinoma: Ectopic lymphoid structures promote carcinogenesis in the liver. Nat Rev Gastroenterol Hepatol (2015) 0.75
Potential of Cells and Cytokines/Chemokines to Regulate Tertiary Lymphoid Structures in Human Diseases. Immune Netw (2016) 0.75
Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma. Front Oncol (2016) 0.75
Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment. J Immunol Res (2016) 0.75
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol (2016) 0.75
Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival. Biomaterials (2017) 0.75
Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer? Front Immunol (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem (2011) 10.11
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Regulation of adaptive immunity by the innate immune system. Science (2010) 8.00
Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell (2006) 5.97
Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science (1999) 5.95
DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis (2000) 5.09
Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat Biotechnol (2001) 4.82
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity (2006) 3.74
Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol (2006) 3.15
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics (2007) 2.83
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J Biol Chem (2005) 2.43
N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther (1996) 2.24
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene (2003) 1.93
The pathology of hepatitis C. Hepatology (1992) 1.92
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 1.81
Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology (1998) 1.75
Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab (2014) 1.73
Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol (2014) 1.72
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70
Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. Mol Cell (2012) 1.61
CGHregions: dimension reduction for array CGH data with minimal information loss. Cancer Inform (2007) 1.49
Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol (2013) 1.37
Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol (2011) 1.36
Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res (2014) 1.36
Evolution of inflammatory diseases. Curr Biol (2012) 1.27
Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut (2012) 1.22
Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol (2009) 1.17
Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C. Hepatology (1999) 1.16
The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology (1993) 1.12
NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Lett (2002) 1.04
T cell-derived lymphotoxin regulates liver regeneration. Gastroenterology (2008) 1.01
Spatiotemporal basis of innate and adaptive immunity in secondary lymphoid tissue. Annu Rev Cell Dev Biol (2014) 1.00
Tumor necrosis factor, lymphotoxin and cancer. IUBMB Life (2010) 0.84
Lymphotoxin, NF-ĸB, and cancer: the dark side of cytokines. Dig Dis (2012) 0.83
Tertiary lymphoid tissue: A gateway for T cells in the tumor microenvironment. Oncoimmunology (2014) 0.82
Hepatocyte-specific activation of NF-kappaB does not aggravate chemical hepatocarcinogenesis in transgenic mice. J Pathol (2009) 0.81
Histopathology of HCV infection. Clin Liver Dis (1997) 0.80
Lymphotoxin's link to carcinogenesis: friend or foe? from lymphoid neogenesis to hepatocellular carcinoma and prostate cancer. Adv Exp Med Biol (2011) 0.77
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology (2015) 1.09
Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01
Cancer biomarker discovery and validation. Transl Cancer Res (2015) 0.96
Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res (2011) 0.93
Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.91
Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol (2016) 0.91
Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int (2015) 0.83
HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study. PLoS One (2013) 0.82
Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial. Hepatol Res (2016) 0.80
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. Drug Des Devel Ther (2014) 0.80
Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res (2015) 0.79
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrob Agents Chemother (2015) 0.78
Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver. Oncotarget (2014) 0.78
Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. Hepatol Res (2016) 0.77
Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogues. Hepatol Res (2016) 0.77
Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res (2014) 0.76
The Herzenberg lecture: how to make a B-1 cell? Ann N Y Acad Sci (2015) 0.75
Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice. Blood (2016) 0.75
Galectin-1 is essential for efficient liver regeneration following hepatectomy. Oncotarget (2016) 0.75
Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) (2015) 0.75
Use of big data in drug development for precision medicine. Expert Rev Precis Med Drug Dev (2016) 0.75
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol (2016) 0.75
Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients. Hepatol Res (2016) 0.75
Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus. J Am Acad Dermatol (2014) 0.75
Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol (2017) 0.75
Efficacy and safety of telaprevir with natural human interferon beta and ribavirin in Japanese chronic hepatitis C patients with depression. Hepatol Res (2017) 0.75
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in HCV Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother (2017) 0.75
The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings. Liver Int (2017) 0.75
Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir. J Med Virol (2017) 0.75
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses. J Clin Pharmacol (2017) 0.75
Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus. J Med Virol (2017) 0.75
Post-transcriptional 3´-UTR cleavage of mRNA transcripts generates thousands of stable uncapped autonomous RNA fragments. Nat Commun (2017) 0.75
Slfn2 mutation-induced loss of T cell quiescence leads to elevated de novo sterol synthesis. Immunology (2017) 0.75
Clinical significance of hepatectomy for primary biliary cirrhosis patients with hepatocellular carcinoma: Report of a single center case series and review of the published work. Hepatol Res (2013) 0.75
Implication of an extremely high preoperative alpha-fetoprotein value (>4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma. Surgery (2015) 0.75
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Adv Ther (2017) 0.75